BIOMARKERS FOR NOD2 AND/OR RIP2 ACTIVITY RELATED APPLICATION
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Oct 15, 2015
app pub date -
Oct 28, 2013
filing date -
Oct 26, 2012
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
A method of predicting RIP2 inhibitor efficacy in treating a subject with an inflammatory disorder includes obtaining a bodily sample from the subject, determining in the bodily sample the expression level(s) of at least one gene selected from the group consisting of cd40, Clec4E, clec5a, CxCL10, gpr84, Icam1, Irgl, Marcks11, pde4b, Ptges, Rasgrp1, and slc2a6,comparing the expression levels of the at least one gene with the corresponding control value(s), and characterizing the subject as being responsive to RIP2 inhibitor treatment if the expression levels of the at least one gene is increased compared to the corresponding control value(s).
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully